![](https://retinauk.org.uk/wp-content/uploads/2024/04/OCGN-87ae5839.png)
Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Welcome to Retina UK
We are a charity supporting people affected by inherited sight loss and investing in medical research to help make their challenges a thing of the past.
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.
Different inherited sight loss conditions present noticeable symptoms at different times.
Find out how genetic testing may help you and your family discover more about your inherited sight loss condition and how to unlock choices.
Come together for Retina UK Day on Thursday, 10 October 2024 and help us raise awareness and funds for those who are living with inherited sight loss.
The Retina UK Professionals’ Conference is aimed at anyone who works with our community in a professional capacity.
The Retina UK Annual Conference will be held on Saturday 28 September. You can join the Conference in-person or online.